Pluri Inc. (NASDAQ:PLUR) Shares Shorted: Short Interest Up 265.2% in October

Pluri Inc. (NASDAQ:PLUR) was the target of a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 76,809 shares, a growth of 265.2% from the October 15th total of 21,034 shares. Currently, 1.1% of the shares of the stock are short sold. Based on an average daily volume of 97,344 shares, the days-to-cover ratio is presently 0.8 days.

Pluri Trading Down 9.1%

NASDAQ PLUR traded down $0.11 on Thursday, reaching $1.09. The stock had a trading volume of 13,056 shares, compared to its average volume of 21,947. The business has a 50 day moving average price of $1.11 and a 200 day moving average price of $2.30. Pluri has a 1 year low of $0.85 and a 1 year high of $4.87. The company has a market capitalization of $13.76 million, a price-to-earnings ratio of -0.45 and a beta of 0.64.

Pluri (NASDAQ:PLUR) last announced its quarterly earnings results on Thursday, September 10th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.12. The business had revenue of $0.34 million for the quarter, compared to analyst estimates of $0.66 million.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 26th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Pluri has a consensus rating of “Sell”.

Insider Buying and Selling at Pluri

In related news, Director Alexandre Weinstein Manieu purchased 833,334 shares of Pluri stock in a transaction dated Friday, October 23rd. The stock was bought at an average cost of $1.50 per share, with a total value of $1,250,001.00. Following the purchase, the director owned 2,083,334 shares in the company, valued at approximately $3,125,001. The trade was a 66.67% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 43.16% of the company’s stock.

About Pluri

Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification. Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.